Showing results (11-20 of 30) with videos related to

Sort By:
Pageof 3
Cancer Chemotherapy and Pharmacology|January 1, 1994
The pharmacokinetics of high-dose epirubicin and of the cardioprotector ADR-529 given together with cyclophosphamide, 5-fluorouracil, and tamoxifen in metastatic breast-cancer patientsP Jakobsen, B Sørensen, L Bastholt, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1994
The cardioprotector ADR-529 and high-dose epirubicin given in combination with cyclophosphamide, 5-fluorouracil, and tamoxifen: a phase I study in metastatic breast cancerB Sørensen, L Bastholt, M R Mirza, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 23, 2020
The forefront of ovarian cancer therapy: update on PARP inhibitorsM R Mirza, R L Coleman, A González-Martín, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 5, 2015
ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: diagnosis, treatment and follow-upN Colombo, C Creutzberg, F Amant, et al.
European Journal of Cancer (Oxford, England : 1990)|April 10, 2019
Combining conventional therapy with immunotherapy: A risky business?A Coosemans, A Vankerckhoven, T Baert, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 2, 2024
Adding immunotherapy to first-line treatment of advanced and metastatic endometrial cancerG Bogani, B J Monk, M A Powell, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|December 6, 2003
First-line treatment of ovarian cancer FIGO stages IIb-IV with paclitaxel/epirubicin/carboplatin versus paclitaxel/carboplatinG B Kristensen, I Vergote, G Stuart, et al.
Gynecologic Oncology|June 29, 2024
NSGO-OV-UMB1/ENGOT-OV30: A phase II study of durvalumab in combination with the anti-CD73 monoclonal antibody Oleclumab in patients with relapsed ovarian cancerM R Mirza, L Tandaric, J R Henriksen, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 3, 2021
European experts consensus: BRCA/homologous recombination deficiency testing in first-line ovarian cancerI Vergote, A González-Martín, I Ray-Coquard, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 14, 2016
Poor concordance between CA-125 and RECIST at the time of disease progression in patients with platinum-resistant ovarian cancer: analysis of the AURELIA trialK Lindemann, G Kristensen, M R Mirza, et al.
Pageof 3